Lymphatics proliferate, become enlarged, or regress in multiple inflammatory lung diseases in humans. Lymphatic growth and remodeling is known to occur in the mouse trachea in sustained inflammation, but whether intrapulmonary lymphatics exhibit similar plasticity is unknown. We examined the time course, distribution, and dependence on vascular endothelial growth factor receptor (VEGFR)-2/VEGFR-3 signaling of lung lymphatics in sustained inflammation. Lymphatics in mouse lungs were examined under baseline conditions and 3 to 28 days after Mycoplasma pulmonis infection, using prospero heomeobox 1e enhanced green fluorescence protein and VEGFR-3 as markers. Sprouting lymphangiogenesis was evident at 7 days. Lymphatic growth was restricted to regions of bronchus-associated lymphoid tissue (BALT), where VEGF-Ceproducing cells were scattered in T-cell zones. Expansion of lung lymphatics after infection was reduced 68% by blocking VEGFR-2, 83% by blocking VEGFR-3, and 99% by blocking both receptors. Inhibition of VEGFR-2/VEGFR-3 did not prevent the formation of BALT. Treatment of established infection with oxytetracycline caused BALT, but not the lymphatics, to regress. We conclude that robust lymphangiogenesis occurs in mouse lungs after M. pulmonis infection through a mechanism involving signaling of both VEGFR-2 and VEGFR-3. Expansion of the lymphatic network is restricted to regions of BALT, but lymphatics do not regress when BALT regresses after antibiotic treatment. The lung lymphatic network can thus expand in sustained inflammation, but the expansion is not as reversible as the accompanying inflammation. (Am J Pathol 2014, 184: 1577e1592; http://dx.doi.org/10.1016/j.ajpath.2014.01.021)
Lymphatic vessels undergo changes in many inflammatory lung diseases, where lymphatic proliferation, enlargement, and regression have been described. 1, 2 Examples include asthma, where lymphatics regress, 3 chronic obstructive pulmonary disease (COPD) and pneumonia, where they proliferate, 4e6 and idiopathic pulmonary fibrosis, where they undergo abnormal growth and remodeling in the lung parenchyma 7, 8 but regress in subpleural and interlobular compartments. 9 Although lymphatics are well known to drain interstitial fluid and serve as conduits for antigen-presenting cells and lymphocytes from the lung, 10e12 little has been learned about the mechanism and functional implications of lymphatic changes in pulmonary inflammation. Regardless of the impact of lymphangiogenesis on disease pathophysiological characteristics, the presence of edema in inflammatory lung disease indicates that the amount of plasma leakage exceeds the fluid drainage capacity through lymphatics and other routes.
Lymphatics proliferate in many settings of sustained inflammation, including psoriasis, 13 rheumatoid arthritis, 14 and inflammatory bowel disease, 15 but it is still unclear whether proliferation of lymphatics worsens or ameliorates disease severity. Promotion of lymphatic growth by transgenic overexpression of vascular endothelial growth factor (VEGF)-C reduces the severity of skin inflammation. 16 This effect has not been examined in the lung, and it is unknown whether it is typical of inflammatory conditions in other organs. It is also unclear whether lung lymphatics exhibit the same plasticity in inflammation as those in other organs.
Previous studies had shown that tracheal lymphatics undergo widespread growth and remodeling after infection. During the first 4 weeks after infection, tracheal lymphatics undergo even more extensive changes than blood vessels. 17, 18 However, sensitization and challenge of lungs to house dust mite allergen for 2 weeks has no detectable effect on the number of lung lymphatics. 19 Little is known about the effects on lung lymphatics of other conditions of sustained inflammation.
We, therefore, used a mouse model of sustained lung inflammation produced by respiratory tract infection by Mycoplasma pulmonis bacteria to determine the response of lung lymphatics to sustained inflammation and to compare changes in the lung with those in the trachea. With the presumption that lymphangiogenesis does occur in the lung, we sought to determine exactly when and where. During the period of 1 to 4 weeks after infection, we closely observed the distribution of the changes in the lung to address the possibility that lymphatic growth or remodeling was regionally specific.
We also investigated the driving mechanism for lymphatic growth in lungs in this model. Because of compelling evidence that lymphatic growth in the trachea and other settings is driven by VEGF-C activation of VEGF receptor (VEGFR)-3 signaling, 20 we compared the effects in the lung and trachea of blocking VEGFR-2 and VEGFR-3 administered individually or together.
Consistent with this reasoning, previous studies revealed that lymphangiogenesis in the trachea after M. pulmonis infection was completely inhibited by a function-blocking antibody to VEGFR-3. 17 Similar results have been obtained in skin 21 and cornea. 22 However, lymphangiogenesis under some conditions is also partially reduced by selective inhibition of VEGFR-2, examples being skin, 23 cornea, 24 lymph nodes, 25 arthritic joints, 24 and tumors. 26 The latter mechanism could reflect effects of VEGFR-2 blockade directly on lymphatics or indirectly through changes in leukocytes or other cells that produce lymphangiogenic factors.
The present study of lymphatic remodeling in sustained bronchopneumonia produced by M. pulmonis infection addressed the question of whether lymphatics grow, undergo remodeling, or regress during the development of bronchopneumonia. The study also examined the time course of changes in lymphatics, whether the distribution of lymphangiogenesis coincides with the widespread inflammatory changes in the lung, and whether lymphatic growth and remodeling in the lung is driven by changes in signaling of VEGFR-3, VEGFR-2, or both.
The experiments revealed that some lymphatics in the lung underwent profound changes after M. pulmonis infection. Sprouting lymphangiogenesis was evident at 1 week and was more pronounced at 2 and 4 weeks. Strikingly, expansion of the lymphatic network was restricted to regions of bronchus-associated lymphoid tissue (BALT) that formed in the lung around bronchi and major pulmonary vessels. Lymphatics in more peripheral regions of the lung did not exhibit these changes, despite the presence of inflammatory cells. Growth of lymphatics in BALT was blocked 99% by inhibition of VEGFR-2 and VEGFR-3 together. Inhibition of VEGFR-3 alone resulted in 83% reduction, whereas inhibition of VEGFR-2 alone resulted in 68% reduction. Inhibition of lymphangiogenesis in BALT by blocking VEGFR-2 and VEGFR-3 did not prevent the formation of BALT.
Materials and Methods

Mice
Mice used were C57BL/6 strain, specific pathogen free, and housed under barrier conditions. They included wild-type mice (Charles River, Hollister, CA), prospero heomeobox 1 (Prox1)eenhanced green fluorescence protein (EGFP)e transgenic mice with fluorescent green lymphatics, 27 and CC10eVEGF-Aetransgenic mice overexpressing human VEGF-A in epithelial cells of airways and lungs. 28 Mice were anesthetized by i.m. injection of 87 mg/kg ketamine and 13 mg/kg xylazine. The Institutional Animal Care and Use Committee of the University of California, San Francisco, approved all experimental procedures.
M. pulmonis Infection and Antibiotic Treatment
Anesthetized mice were infected with M. pulmonis by intranasal inoculation of 25 mL per nostril of broth containing a total of 10 6 colony-forming units of organisms (strain CT7), as described previously. 17 In some experiments, mice were treated for 14 days by daily i.p. injection of 100 mg/kg oxytetracycline (Liquamycin; Pfizer, Sao Paulo, Brazil) to eliminate the infection.
Inhibition of VEGF-2 and/or VEGFR-3 Signaling
Function-blocking rat monoclonal antibodies were used to block VEGFR-2 (clone DC101) and/or VEGFR-3 (clone mF4-31C1) (ImClone Systems, New York, NY). 17 Antibodies were injected i.p. at a dose of 0.8 mg in a volume of 200 mL of 0.9% sterile NaCl solution per mouse 1 day before infection, then every other day for 14 days. Rat IgG (Jackson ImmunoResearch Labs Inc., West Grove, PA) was used as a control.
Fixation and Tissue Preparation
The vasculature of anesthetized mice was perfused for 2 minutes at a pressure of 120 to 140 mmHg with fixative (1% paraformaldehyde in PBS, pH 7.4; Sigma-Aldrich, St. Louis, MO) from a cannula inserted through the left ajp.amjpathol.org -The American Journal of Pathology ventricle into the aorta. In some cases, the pulmonary circulation was first flushed by insertion of the cannula into the right ventricle at the origin of the pulmonary artery and perfusion at a pressure of 20 mmHg until the lungs turned white. To preserve alveoli in an expanded condition, lungs were inflated with 0.4 mL of melted 1% SeaPlaque lowmelting point agarose (Lonza, Rockland, ME) in PBS slowly administered intratracheally via a syringe and an 18gauge catheter. Tracheas, bronchial lymph nodes, and lungs were removed, weighed, and immersed in fixative for 1 hour at 4 C and then washed with PBS. The left lung was cut transversely into three parts, such that the middle part contained the main bronchus and the major pulmonary blood vessels were cut in cross section approximately 3 mm below the hilum ( Figure 1 ). The left lung sections and whole right lungs were embedded flat in Tissue-Tek medium (Sakura, Torrance, CA) and frozen as cryostat blocks.
IHC Data
Tissues were washed and stained immunohistochemically (IHC) by incubating cryostat sections (200 mm thick) of the mid left lung cut transversely or whole mounts of trachea with one or more primary antibodies diluted in PBS containing 0.3% Triton X-100 (Sigma-Aldrich), 0.2% bovine serum albumin (Sigma-Aldrich), 10% normal serum (Jackson ImmunoResearch Labs Inc.), and 0.1% sodium azide (Sigma-Aldrich). 17 We used the following antibodies to identify blood vessels: platelet endothelial cell adhesion molecule (PECAM)-1 (CD31) (hamster anti-mouse monoclonal, clone 2H8, MA3105; Thermo Fisher Scientific, Rockford, IL); lymphatics, such as VEGFR-3 (goat anti-mouse polyclonal AF743; R&D Systems, Minneapolis, MN); lymphatic vessel endothelial cell marker (LYVE)-1 (rabbit anti-mouse polyclonal 11-034; AngioBio, Del Mar, CA); podoplanin (Syrian hamster anti-mouse monoclonal, clone 8.1.1; AngioBio); neuropilin-2 (goat polyclonal AF567; R&D Systems); chemokine ligand (CCL) 21 (goat polyclonal AF457; R&D Systems); VEGF-C (goat polyclonal sc-7132; Santa Cruz Biotechnology, Dallas, TX); Prox1 (rabbit anti-mouse polyclonal AB5475; Millipore, Billerica, MA); smooth muscle cells, such as a-smooth muscle actin (aSMA; mouse monoclonal, clone 1A4 conjugated to fluorescein isothiocyanate, F3777, or Cy3; C6198; Sigma-Aldrich); pan-leukocyte marker CD45 (rat anti-mouse monoclonal, clone 30-F11; BioLegend, San Diego, CA); B lymphocytes, such as B220 (rat anti-mouse monoclonal, clone RA3-6B2; BD Biosciences, San Jose CA); T lymphocytes, such as CD3e (Armenian hamster anti-mouse monoclonal, clone 145-2C11; BD Biosciences); macrophages and dendritic cells, such as allograft inflammatory factor 1/ionized calcium-binding protein 1 (Aif1/Iba1; Wako USA, Richmond, VA); neutrophils, such as S100A8 (goat polyclonal AF3059; R&D Systems); high endothelial venules (HEVs), such as MECA-79 (PNAd carbohydrate epitope, CD62L, rat anti-mouse monoclonal, clone MECA-79; BD Biosciences); lung epithelial cells (primarily alveolar type 1 cells), such as aquaporin-5 (rabbit polyclonal ab78486; Abcam, Cambridge, MA) or pan-cytokeratin (rabbit polyclonal Z0622; Dako USA, Carpinteria, CA); epithelial microfold cells (M cells), such as biotinylated Ulex europaeus lectin B1065 (Vector Laboratories, Burlingame, CA); and endogenous EGFP fluorescence, amplified by chicken polyclonal anti-GFP (GFP-1020; Aves Labs, Tigard, OR).
Secondary antibodies were labeled with Dy488 or Alexa488, Cy3, or Cy5 or Dy649 (Jackson ImmunoResearch Labs Inc.). Specimens were viewed with a Zeiss Axiophot fluorescence microscope (Zeiss USA, Thornwood, NY) equipped with a threeecharge-coupled device low-light red, green, blue (RGB) video camera (CoolCam; SciMeasure, Decatur, GA) or a Zeiss LSM-510 confocal microscope using AIM 4.0 confocal software version 4.0 (Zeiss USA).
Preliminary experiments showed that the most effective markers for lymphatics in mouse lungs were EGFP in Prox1-EGFPetransgenic mice and VEGFR-3. The IHC amplified Prox1-EGFP provided strong staining of lymphatics with little or no background staining. Other conventional markers, including LYVE-1 and podoplanin (gp38, T1a), were not as useful for identifying lymphatics in mouse lung because of expression in other cell types (Supplemental Figure S1 , A and B). Pulmonary blood vessels and tissue macrophages had strong LYVE-1 immunoreactivity. Type 1 alveolar epithelial cells had strong podoplanin immunoreactivity. Immunoreactivity for neuropilin-2, a coreceptor for VEGFR-3, was stronger in smaller-than in larger-diameter lymphatics (Supplemental Figure S1C ).
Measurement of Lymphatics and BALT
The area density of lymphatics was measured in transverse sections (200 mm thick) of the middle portion of the left lung. The left lung, consisting of only one lobe, was used for measurements because of its simpler structure compared with the multiple-lobed right lung. To identify the main stem bronchus, pulmonary artery, and pulmonary vein and provide a reference framework for the lymphatics, we stained smooth muscle cells in the walls of airways and blood vessels for aSMA. 19 For morphometry, lung slices were stained for VEGFR-3 instead of Prox1-EGFP, which was also expressed in cardiac muscle cells of the proximal portion of the pulmonary vein and tended to obscure the surrounding lymphatic vessels. Sections of the midportion of the left lung were imaged with 10Â (numerical aperture, 0.5) objective lenses linked to a video camera and digitizing tablet, and images were projected onto a color monitor, as described previously. 17 A rectangular survey box with an area of 0.134 mm 2 consisting of 126 points arranged in a simple square grid was superimposed on the projected image of each of four regions: the main stem bronchus, pulmonary vein, pulmonary artery, and lung parenchyma. The survey box was positioned with one edge located along the transversely cut edge of the bronchus, pulmonary artery, or pulmonary vein, as identified by staining for aSMA so that the box contained lymphatics associated only with that particular structure ( Figure 1 ). For the lung parenchyma, the survey box was positioned over regions of the peripheral lung that had minimal aSMA immunoreactivity. The number of survey grid points overlying tubular structures corresponding to lymphatics was counted and expressed as a percentage of the total. Lungs from at least five mice per group were counted for each condition. For comparison, lymphatic area densities were also determined in whole mounts of tracheas stained for LYVE-1 immunoreactivity, with the survey box positioned over the regions of mucosa overlying the cartilage rings. 17 The diameter of lymphatics was measured in sections stained for VEGFR-3 or Prox1-EGFP. BALT was quantified by measuring the area of regions of densely packed lymphoid cells in H&E-stained sections of the midportion of the left lung with the digitizing tablet at a magnification of Â75 and was expressed as a percentage of total lung area.
Statistical Analysis
Values are presented as means AE SEM, with at least five mice per group unless otherwise indicated. The significance of differences between groups was assessed by analysis of variance, followed by the Dunn-Bonferroni test for multiple comparisons, with P < 0.05 considered significant.
Results
Distribution of Lymphatics in Normal Lung
The effect of M. pulmonis infection on lung lymphatics was determined by first obtaining baseline data for the distribution of lymphatics in the lungs of pathogen-free mice. The approach was to visualize lymphatics by immunofluorescence staining for Prox1-EGFP or VEGFR-3 in thick slices of the midportion of the left lung of mice ( Figure 1 ). Smooth muscle cells of airways and blood vessels in the slices were similarly stained for aSMA to serve as reference structures.
Most lymphatics in lungs of pathogen-free mice were located around large bronchi and major blood vessels near the hilum (Figure 2A ). Bronchi, pulmonary arteries, and pulmonary veins could be distinguished from one another by their characteristic arrangement of smooth muscle cells. A common network of lymphatics surrounded pairs of bronchi and pulmonary artery branches ( Figure 2 , A and B). A seemingly separate lymphatic network surrounded pulmonary veins (Figure 2 , CeE). Lymphatics accompanied airways and blood vessels into the lung parenchyma. The lymphatic network extended further distally along the branches of pulmonary veins than pulmonary arteries or airways of comparable diameter ( Figure 2C ).
The number and distribution of lymphatics around bronchi, pulmonary artery, pulmonary vein, and distal regions of the lung under pathogen-free conditions provided a reference for understanding changes that occurred after infection. Near the lung hilum, lymphatics were comparably numerous around the main stem bronchus, pulmonary artery, and pulmonary vein ( Figure 2F ). However, lymphatics were <20% as abundant in alveolar regions containing only small airways or blood vessels of the distal lung parenchyma. In pathogen-free lungs, the mean diameter of the largest lymphatics was 60 AE 7 mm at their entry at the hilum and 38 AE 7 mm on mediumsized airways and vessels. The smallest lymphatics detected on terminal branches of pulmonary veins (Figure 2 , CeE) had a diameter of 9 AE 1 mm. Even near alveoli and visceral pleura, lymphatics were typically associated with airways and blood vessels (Figure 2 , CeE). Few lymphatics were located within or beneath the visceral pleura ( Figure 2 , A, C, and E).
Expansion of Lung Lymphatic Network after M. pulmonis Infection
Lymphatics were conspicuously more abundant in lungs of infected mice than in lungs of pathogen-free mice ( Figure 3H ). These data revealed that the lymphatic network expanded threefold during the first 7 days after infection and continued to increase to approximately sixfold at 28 days ( Figure 3H ). In sharp contrast to these regions, lymphatics in the lung parenchyma did not increase after infection ( Figure 3H ). Few sprouts were found on lymphatics on distal regions of lung parenchyma, including small bronchi, blood vessels (Supplemental Figure S2A) , and visceral pleura.
Further changes in lung lymphatics after infection included stronger CCL21 immunoreactivity in lymphatic endothelial cells (Supplemental Figure S2, BeG) . CCL21 was widespread in lung lymphatics after infection, was relatively specific to lymphatic endothelial cells, and contrasted with weak staining in pathogen-free lungs, where it was restricted to the perinuclear region of lymphatic endothelial cells (Supplemental Figure S2, BeG) . No change was detected in the intensity of VEGFR-3 or Prox1-EGFP immunoreactivity in lymphatics after infection. LYVE-1 and podoplanin antibodies proved to be unsuitable for staining lymphatics in the lung because they also labeled other cell types. Immunoreactivity for neuropilin-2, a coreceptor for VEGFR-3, was not uniformly strong on lymphatics of all sizes to be used as a reliable marker (Supplemental Figure S1 , AeC).
In search of potential drivers of lymphatic growth and remodeling after infection, we examined the distribution and abundance of cells that express the potent lymphangiogenic factor, VEGF-C. We found that VEGF-Ceimmunoreactive cells were located preferentially in BALT around large bronchi and pulmonary vessels ( Figure 3 , I and J). VEGF-Cepositive cells were numerous in regions of the expanded lymphatic network in BALT, but were sparse or absent in the adjacent lung parenchyma ( Figure 3I ). Staining for CD45 identified the VEGF-Ce immunoreactive cells as a subpopulation of mononuclear leukocytes ( Figure 3J ).
Preferential Growth of Lymphatics in BALT after M. pulmonis Infection
Distribution of Inflammation after Infection
The progression of lung inflammation after M. pulmonis infection was examined in H&E-stained sections at 0, 7, 14, and 28 days after infection. Two concurrent processes were evident: formation of cuffs of lymphoid tissue around inflamed airways and major blood vessels and accumulations of inflammatory cells in alveoli typical of lobar pneumonia ( Figure 4A ). Peribronchial and perivascular accumulations of lymphoid tissue fit with published descriptions of BALT. 29e33 Cell infiltration increased with duration of infection, and at 28 days, some regions of lung parenchyma were consolidated by inflammatory cell infiltrate ( Figure 4, A and B) .
The amount of BALT increased from none in pathogenfree lungs to an average of >15% of the total lung area at 28 days of infection, but it varied among mice at each time point and at 28 days ranged from almost none to 30% ( Figure 4C ). The mean wet weight of the left lung increased 2.5-fold during this period ( Figure 4D ). Typical of BALT, the lymphoid aggregates contained HEVs, sites of lymphocyte homing identified by the presence of peripheral node addressin marked by MECA-79 antibody ( Figure 4E ). In addition, the airway epithelium overlying BALT contained M cells, which are sites specialized for antigen entry identified by U. europaeus lectin binding ( Figure 4F ). 31, 34 Lymphatics were most abundant in regions of loosely packed T cells around, but not inside, B-cell follicles of BALT (Figure 4, GeI) .
Time Course of Sprouting Lymphangiogenesis in BALT
The temporal relationship between lymphocyte influx, BALT formation, and lymphangiogenesis was examined during early stages of infection. Pathogen-free lungs had few B or T cells (Supplemental Figure S3 , AeC). At 3 days of infection, the number of T cells was conspicuously increased throughout the lung parenchyma. This was the earliest time point when clusters of lymphocytes, especially T cells, were found near lymphatics (Supplemental Figure S3 , DeF). At 3 days, lymphatics appeared normal, but at 5 days, sprouts were present on lymphatics, and B-cell follicles were evident around airways and large vessels (Supplemental Figure S3G ). T and B cells were present in the lumen of some lymphatics (Supplemental Figure S3 , H and I).
Diverse Inflammatory Cells in BALT and Lung Parenchyma after Infection
Macrophages, dendritic cells, and neutrophils were abundant along T and B cells in BALT. Macrophages and dendritic cells, identified by immunoreactivity for Aif1/Iba1, were sufficiently numerous to delineate the margins of BALT ( Figure 4J ). Neutrophils, identified by S100A8 immunoreactivity, were scattered in BALT but were much more abundant in the airway lumen ( Figure 4K ). These inflammatory cells were also abundant in the lung parenchyma of infected mice (Figure 4 , L and M). Lymphatics in BALT and distal branches of pulmonary veins in the lung parenchyma coursed through macrophage-and neutrophilrich regions (Figure 4 , L and M), but only the lymphatic network in BALT underwent conspicuous expansion.
Contribution of VEGFR-3 and VEGFR-2 Signaling to Lymphangiogenesis in Lung Effect of Blocking VEGFR-3 and/or VEGFR-2 on Lung Lymphatics
To determine the contribution of VEGFR-3 and/or VEGFR-2 signaling to the expansion of the lung lymphatic network after infection, we treated mice with function-blocking antibodies to VEGFR-3 and/or VEGFR-2 from the onset of infection, and measured the abundance of lymphatics at 14 days. Lymphatics in both the lung and the trachea were
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As a reference, tracheal lymphatics increased 12-fold over the pathogen-free value during infection for 14 days in mice that received control rat IgG (Supplemental Figure S4,  A and B) . The increase was 40% less in mice treated with the VEGFR-2eblocking antibody DC101 (Supplemental Figure S4C ) and 98% less in mice treated with the VEGFR-3eblocking antibody mF4-31C1 (Supplemental Figure S4 , D and F). Tracheal lymphatics in infected mice receiving the antieVEGFR-2 and antieVEGFR-3 antibodies together were similar to those receiving anti-eVEGFR-3 alone (Supplemental Figure S4 , E and F). Both resembled the lymphatics in pathogen-free controls.
The results were similar, but not identical, in the lung (Figure 5, AeF) . The infected group that received control IgG had a fourfold increase in lung lymphatics over the pathogenfree baseline ( Figure 5, A and B) . The apparently greater increase in the trachea was more a reflection of differences in the pathogen-free baseline values in the trachea and lung than amount of increase after infection. Lung lymphatics were 68% less numerous in mice treated with VEGFR-2eblocking antibody ( Figure 5C ), 83% less in mice treated with VEGFR-3eblocking antibody ( Figure 5D ), and 99% less in mice treated with both antibodies together ( Figure 5 , E and F). None of the treatments had a measurable effect on the abundance of lymphatics in the lung parenchyma ( Figure 5F ). Values for trachea and lung in the same mice had a significant correlation by linear regression analysis, with a coefficient of determination R 2 of 0.54 (P < 0.05).
Effect of Blocking VEGFR-3 and/or VEGFR-2 on BALT and Lymph Nodes
The overall effect on lung inflammation of blocking VEGFR-3 and/or VEGFR-2 was assessed by examining the amount of BALT ( Figure 5G ) and bronchial lymph node hypertrophy. Measurements of BALT in H&E-stained sections of lungs gave similar values in all infected mice, regardless of antibody treatment ( Figure 5H ), and all infected groups were significantly greater than the amount in pathogen-free mice ( Figure 5H ). The amount of BALT in these treatment groups was similar to that found at 14 days in the earlier time course study ( Figure 4C) .
During the 14-day infection, bronchial lymph nodes increased sixfold in weight. Blocking VEGFR-2 and VEGFR-3 together reduced the weight by 50%, but blocking either VEGFR-2 or VEGFR-3 alone had no significant effect on lymph node weight ( Figure 5I ).
After having learned that blocking VEGFR-2 and/or VEGFR-3 did not change the amount of BALT, we asked if the blood vasculature of BALT was affected, to test the possibility that these inhibitors prevented angiogenesis that normally occurs as lymphoid tissue expands. Studies of BALT vasculature revealed that nonfollicular regions of BALT contained abundant blood capillaries and HEVs. The vessel types were readily distinguished because HEVs were much larger than capillaries ( Figure 5J ). Lymphoid follicles had fewer blood capillaries and no HEVs. When VEGFR-2 and VEGFR-3 were inhibited together throughout the 14day infection, capillaries in BALT were less than half as numerous, but HEVs seemed unaffected ( Figure 5K ).
Lack of Lymphatic Sprouting after Overexpression of VEGF-A
To explore evidence for the involvement of VEGFR-2 in sprouting and growth of lung lymphatics after M. pulmonis infection, we asked whether VEGF-A, a potent ligand for VEGFR-2, made a contribution. To address this question, we used Clara cell secretory protein (CCSP)eVEGF-Ae transgenic mice as a model in which VEGF-A expression, under the control of the CCSP promoter, triggers abundant angiogenesis in the trachea and lung when activated by doxycycline administration. 28 Sections of lungs of CCSPeVEGF-A mice taking doxycycline for 14 days had usually abundant blood vessels in the bronchial mucosa, but no expansion or sprouting of neighboring lymphatics, compared with CCSPeVEGF-A mice taking water (Supplemental Figure S4 , G and H).
Persistence of Lung Lymphatics after Resolution of Infection
To build on our previous observation that newly formed lymphatics persisted in tracheas long after M. pulmonis infection was eliminated by antibiotic treatment, 17 we sought to determine whether the same occurred in the lung. Mice infected for 14 days were then treated for a further 14 days with vehicle or with oxytetracycline to eliminate the infection. The experiment had a clear outcome: BALT was extensive in H&E-stained sections of untreated lung, but was sparse or absent in lungs of infected mice treated with the antibiotic (Figure 6 , AeD and I). However, in the same mice, the abundance of lymphatics around major bronchi and pulmonary vessels was not significantly reduced by oxytetracycline ( Figure 6 , EeH and J). Treatment with the antibiotic had a similar effect on bronchial lymph nodes as on BALT: lymph node weight was reduced almost to pathogen-free levels ( Figure 6K ).
Discussion
We sought to determine the number and distribution of lymphatics in the lung of mice, how lung lymphatics change after
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Relation of Murine M. pulmonis Infection to Human Pulmonary Disease
Mycoplasma pulmonis infection has multiple attributes for studies of sustained lung inflammation because these natural murine pathogens have co-evolved with their host to reach a balance between infection of the respiratory tract and elimination by host immune responses. Compared with transient pulmonary infections or irritants, the inflammatory stimulus provided by M. pulmonis is sustained and consequently leads to progressive pathological characteristics. 29 The mouse model of lymphangiogenesis in sustained lung inflammation reported herein might also be relevant to human pulmonary disease. BALT develops in several human lung diseases, including COPD, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and rheumatoid arthritis, where it may result from opportunistic secondary lung infections. 35, 36 However, we are aware of only one clinical report that mentions the presence of lymphatics in BALT of lungs. 5 The authors of that study concluded that BALT and associated lymphatics contributed to aggravated inflammation in COPD.
Comparison of Lung Lymphatics in Pathogen-Free and Infected Mice
Most lymphatics in lungs of pathogen-free mice, as in other species, accompanied the major bronchi and blood vessels, especially pulmonary veins. Fewer lymphatics were located in the lung parenchyma. These findings are in broad agreement with a recent study of lung lymphatics in pathogen-free mice. 19 Compared with larger organisms, such as rat, 37 sheep, 38 or human, 39 a notable difference in the architecture of lymphatics in mouse lung was their almost complete absence in the visceral pleura.
From the results of previous studies of trachea in M. pulmoniseinfected mice, 17,18,40e42 it seemed likely that lymphangiogenesis would also occur in the lung after infection, but we did not know how, when, or where it would happen. An unexpected finding in the current study was that most of the lymphangiogenesis in lungs after infection occurred in regions of BALT around the major airways and blood vessels. In this respect, our finding differed from that of a report in which no significant changes were found in lymphatics in lung inflammation induced by administration of house dust mite allergen. 19 The reason for the difference is not clear but probably involves the nature, severity, and duration of the inflammatory response under the two conditions.
Time Course of Changes in Lymphatics
In this study, much of the lymphatic growth in the lung occurred within the first 7 days after infection, but lymphangiogenesis continued for at least 28 days. The onset of lymphatic growth was more rapid in the lung than in the trachea, where lymphatic sprouting began around 7 days and was not obvious until 14 days. The slower lymphangiogenesis in the trachea could reflect the spread of infection from the lung to more proximal airways. At any rate, for this reason, we used the 14-day time point to compare the effects of VEGFR-2/VEGFR-3eblocking antibodies in lungs and trachea.
Of the markers of lymphatic phenotype examined, CCL21 was the only one that was clearly greater in infected lungs than in pathogen-free lungs. CCL21 immunoreactivity was increased not only in the newly formed lymphatics but also in the extracellular matrix. These findings are consistent with recent reports of increased CCL21 secretion by inflammatory stimuli, thereby facilitating mobilization and trafficking of dendritic cells and lymphocytes into activated lymphatics. 43e46 Increased CCL21 staining has also been reported on lung lymphatics in patients with COPD. 6 
Relationship of Changes in Lymphatics to other Inflammatory Changes
The present study showed that changes in mouse lung lymphatics after infection happened more or less in parallel with peribronchial and perivascular lymphoid cuffing by BALT and development of pneumonia. Both processes were recognized many years ago in mouse lungs after M. pulmonis infection, 29 but have not previously been examined in the context of lung lymphatics. Lymphangiogenesis was closely associated with the formation of BALT but not with the development of pneumonia.
Although numerous studies confirm that experimental bacterial or viral infection can induce BALT in mouse lungs, 33, 47, 48 lymphatics in BALT have received relatively little attention. 35 The present study showed that the peribronchial and perivascular cuffs in mouse lungs infected with M. pulmonis had all of the features characteristic of BALT, including the presence of HEVs, 32,49 epithelial M cells, 31, 34 and B-cell follicles surrounded by T-cell zones. 30, 32 Our finding that lymphangiogenesis in the lung was largely restricted to BALT after M. pulmonis infection has several implications. First, it suggests that functions of the newly formed lymphatics relate more to BALT than to general fluid balance or cell trafficking in other regions of the lung. For immune cells that enter the lung via HEVs in BALT, the newly formed lymphatics are likely to be an exit route. 11 In this context, the location of lymphatics in peripheral regions of BALT some distance from the airway epithelium indicates that antigens and antigen-presenting cells traverse the thickness of BALT to reach lymphatics. Our observation of leukocytes in the lumen of lymphatics in BALT suggests that the newly formed lymphatics could be functional in terms of immune cell trafficking. The finding of VEGF-C and lymphangiogenesis in BALT suggests that local factors drive lymphatic growth. B cells have been claimed to drive lymphangiogenesis in inflamed lymph nodes. 25 In the present study, VEGF-Cecontaining cells and the newly formed lymphatics were located in Tcell regions of BALT, but not in B-cell follicles. The involvement of T or B cells is suggested by evidence that lymphangiogenesis does not occur after M. pulmonis infection in immunodeficient recombination-activating geneedeficient mice or B-celledeficient mice. 40 There is no consensus on whether BALT is beneficial or detrimental to the host after M. pulmonis infection. Like other features of sustained inflammation, BALT is probably both good and bad for different aspects of disease. Because BALT changes normal lung structure and could affect gas exchange, it would appear to be bad for the lung. However, because BALT could help confine the disease to the airways and lungs and prevent dissemination to distant sites, it would be beneficial for the host overall. In recombinationactivating gene mice, severe combined immunodeficient mice, B-celledeficient mice, and mice treated with the immunosuppressant cyclophosphamide, BALT does not ajp.amjpathol.org -The American Journal of Pathology develop after M. pulmonis infection and the lungs are relatively normal. However, the bacteria disseminate throughout the body and infect the pericardium, liver, spleen, and even joints, where severe arthritis can develop. 40,50e52 Dependency of Lung Lymphatic Growth on VEGFR-3 and VEGFR-2 Signaling
Our studies with blocking antibodies showed that VEGFR-3 signaling was the main, but not the only, driving force for lymphangiogenesis in lungs after M. pulmonis infection. The finding that VEGFR-3 signaling is dominant is consistent with the presence of VEGF-C in inflammatory cells in BALT and with evidence for lymphatic growth in other organs. 20 However, VEGFR-2 signaling also had a role in the lung. The involvement of both VEGFR-3 and VEGFR-2 in lymphangiogenesis has been shown in skin, 23,53e55 lymph nodes, 25, 56 cornea, 57 and tumors. 26 In all locations, VEGFR-3 has the stronger effect. VEGF-A is reported to drive lymphatic growth through VEGFR-2 in embryonic mouse lungs, 58 but, to our knowledge, this has not been examined in adult lungs. The present studies of VEGF-A overexpression in CC10eVEGF-A mice detected no lymphangiogenesis, despite the robust angiogenesis. The relative lack of changes in lymphatics in distal regions of lung parenchyma, despite the presence of abundant inflammatory cells, indicates that the microenvironmental conditions necessary for lymphangiogenesis differ in BALT from other regions of the lung.
How VEGFR-2 signaling contributes to lymphangiogenesis is not well understood. Several direct and indirect mechanisms have been proposed. Because both VEGFR-3 and VEGFR-2 are expressed on lymphatic endothelial cells, 20 it has been proposed that VEGF-A and VEGF-C stimulate their respective receptors to promote different aspects of lymphangiogenesis, radial enlargement, and lymphatic sprouting. 55 VEGF-A, and even more potently VEGF-C, can promote the formation of VEGFR-2/ VEGFR-3 heterodimers that can be activated by either growth factor. 59 Antibodies that prevent VEGFR-3/ VEGFR-2 heterodimer formation can inhibit both angiogenesis and lymphangiogenesis. 60 Signaling through heterodimers can also be influenced by regulatory molecules, such as Bmx kinase, that modulate downstream signaling pathways. 61 VEGF-A can recruit macrophages, promote angiogenesis, and induce plasma extravasation. Because some macrophages secrete VEGF-C, inhibiting VEGFR-2 signaling could reduce lymphangiogenesis by suppressing macrophage influx. 20, 57 Inhibition of VEGFR-2 signaling could also inhibit lymphangiogenesis by reducing plasma leakage and thereby reduce mediators from extravasated plasma that contribute to macrophage or immune cell recruitment, activation of extracellular proteases, or other processes that produce lymphangiogenic factors.
Issues Still to be Resolved about Lung Lymphatics
Further studies will be needed to address the complexities of VEGFR-3/VEGFR-2 interactions in lymphangiogenesis. Experiments using CCSPeVEGF-Aetransgenic mice showed that VEGF-A overexpression in respiratory tract epithelial cells produced angiogenesis without lymphangiogenesis in the lungs. These results are consistent with earlier findings in the trachea, 28 but could appear inconsistent with evidence of the involvement of VEGFR-2 signaling in the growth of lymphatics in the lung after M. pulmonis infection. A possible explanation could be that the human VEGF-A (VEGF165), and not mouse VEGF-A (VEGF164), is overexpressed in this transgenic mouse 62 and could influence the ability to promote VEGFR-3/VEGFR-2 heterodimer formation and downstream signaling in the host mouse.
Among the other issues requiring further work is the identity of cells that produce VEGF-C and/or VEGF-D in inflamed tissues. Additional work is also needed to determine the functionality of new lymphatics that grow in the lung in sustained inflammation. Although many technical challenges need to be overcome, there is hope that live-imaging technologies will provide insights into their function. 12, 46, 63, 64 Although BALT was required for the growth of new lymphatic vessels, the converse appears not to be true. Prevention of lymphangiogenesis by treatment with antibodies that blocked both VEGFR-3 and VEGFR-2 did not prevent BALT development. However, in agreement with previous studies of inflamed skin, 25 the antibody combination did reduce the enlargement of the draining lymph node that occurs in M. pulmonis infection. The mechanism of suppression of lymph node growth is not known, but could involve the reduced cell trafficking and fluid drainage from the inflamed organ to the lymph node and reduced angiogenesis and lymphangiogenesis in the lymph node.
The finding of lymphangiogenesis occurring mainly within BALT in infected lungs resembles features of Hashimoto's thyroiditis in humans and in transgenic mouse models 65, 66 and human renal transplant rejection. 67, 68 Sustained immune cell activity and defective lymphatic drainage are thought to trigger the formation of ectopic germinal centers and lymphangiogenesis in such chronic inflammatory conditions. 69 New patterns of lymph flow are established that result in a self-perpetuating feedback loop that sustains the local immune response. In this way, lymphoid cells and lymphatics are mutually interdependent. Persistence of new lung lymphatics after the infection resolves could accelerate or amplify responses to subsequent infections.
Summary
In this study, we sought to learn how lung lymphatics change in sustained inflammation and to understand the mechanism of the changes. After M. pulmonis infection in C57BL/6 mice, BALT formed around major bronchi and pulmonary blood vessels. As BALT accumulated, lymphatics grew by sprouting
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The American Journal of Pathologyajp.amjpathol.org lymphangiogenesis preferentially within T-cell regions that contained VEGF-Ceproducing CD45-positive cells. The new lymphatics had higher than normal expression of CCL21. Little lymphatic growth occurred in distal regions of lung parenchyma, despite the presence of abundant inflammatory cells in regions of pneumonia. Experiments using functionblocking antibodies revealed that signaling through the two VEGF-Cedriven receptors, VEGFR-3 and VEGFR-2, accounted for 99% of the lymphangiogenesis in the lung under these conditions. The new lymphatics were remarkably persistent after resolution of the infection by treatment with the antibiotic oxytetracycline. The lack of regression of the new lung lymphatics, despite regression of the BALT in which they grew, could exaggerate responses to subsequent infections. ajp.amjpathol.org -The American Journal of Pathology
